ClinicalTrials.gg
Active, not recruitingNCT06824129Updated Nov 2, 2026

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

An observational study in Complicated Urinary Tract Infection, sponsored by QIAGEN Gaithersburg, Inc. Active, not recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational

How we know

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.

Planned enrollment
7th of 14
1,500 · median 1,250
Started
2025
the only one that year
Observational
14 of 31
5 open now
Registered
28th of 31
by date

Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 2025, is one of 14 observational ones, and was the 28th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Urinary Tract Infections with a site in United Kingdom, or all of them as a file.
02

Study summary

Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment

Read the detailed description

The objective of the study is to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment.

The primary objective is to evaluate the performance of QIAstat-Dx cUTI Plus AMR Panel in comparison with the results obtained from the reference method.

The secondary objective of the study is to evaluate the safety ofQIAstat-Dx cUTI Plus AMR Panel with respect to users/operators.

The primary study endpoint will be the results for each analyte obtained from testing prospective specimens with QIAstat-Dx cUTI Plus AMR Panel and Reference Method. Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) will be determined

03

Conditions studied

  • Complicated Urinary Tract Infection

Keywords

  • QIAstat-Dx
  • Clinical Performance Study
  • complicated Urinary infection
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with signs and symptoms of complicated urine infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Specimens from subjects of all ages and demographic characteristics can be enrolled.

    • Specimen must come from patients with suspected cUTI by their healthcare provider:
    • Urine specimen with evidence of pyuria confirmed by positive urine analysis (Dipstick analysis positive for leukocyte esterase or at least 10 White Blood Cells percubic millimeter) And
    • A sign or symptom of a cUTI (for example: chills or rigors or warmth associated with fever, malaise, flank pain or pelvic pain and/or costo-vertebral angle pain or tenderness on physical examination, nausea or vomiting, dysuria, urinary frequency or urinary urgency)
    • Specimen must be residual leftover and de-identified
    • Specimen obtained preserved (containing boric acid, sodium formate or sodium borate) or unpreserved as midstream urine or fresh urine catheter
    • For Preserved Only: Fresh prospectively collected preserved specimens stored to up 48 hours at 15°C-25°C or 24 hours at 2°C-8°C.
    • For Unpreserved Only: Fresh prospectively collected unpreserved specimens stored up to 24 hours at 2°C-8°C.
    • Specimen must have a minimum of 3 ml of urine available.
    • Specimen date of collection and standard of Care testing results should be available.
    • Specimen must be unique (only one sample enrolled per patient).

Exclusion criteria

Exclusion Criteria:

  • Specimens enrolled in the study may be excluded for the following reasons:

    • Lack of clear subject identification or label on urine specimen.
    • Specimen has been centrifuged.
    • Obvious physical damage of residual specimen.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. PPA

    Positive percent agreement

    Time frame: 8 months

  2. NPA

    Negative percent agreement

    Time frame: 8 months

07

Study locations

1 site
  • QIAGEN
    Manchester, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 84 observational studies under Urinary Tract Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 13, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Dec 2026was Sep 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2026
Nov 2, 2026
Study completion
Sep 2026→Dec 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Aug 2026→Dec 2026
    Study completion Sep 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06824129
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Dec 23, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Sarah Johnson
principal investigator · Qiagen Manchester Limited

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion